Why the study?
Hypertensive cardiac remodelling commonly causes heart failure, but its underlying molecular mechanisms and the role of PKM2 in this process remain unknown.
Does PKM2 inhibition reduce Angiotensin II-induced cardiac remodelling in preclinical models?
Does PKM2 inhibition reduce Angiotensin II-induced cardiac remodelling in preclinical models?
PKM2 inhibition with shikonin attenuates Angiotensin II-induced cardiac remodelling and fibrosis by suppressing TGF-β/Smad2/3 and Jak2/Stat3 pathways and oxidative stress in preclinical models.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for PKM2 inhibition in remodeling; leaves open translation to human HF therapy.
Zhang et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: